+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 62 Pages
  • March 2022
  • GlobalData
  • Orexo AB
  • ID: 1367943
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:


  • Business description - A detailed description of the company’s operations and business divisions
  • Corporate strategy - Analyst’s summarization of the company’s business strategy
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats
  • Company history - Progression of key events associated with the company
  • Major products and services - A list of major products, services and brands of the company
  • Key competitors - A list of key competitors to the company
  • Key employees - A list of the key executives of the company
  • Executive biographies - A brief summary of the executives’ employment history
  • Key operational heads - A list of personnel heading key departments/functions
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history

Highlights


Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar, and Zubsolv. The company develops its products based on its proprietary drug delivery technology, namely, sublingual tablet technology. The sublingual tablet rapidly disintegrates and dissolves, allowing the medicine to be directly absorbed into the bloodstream through the mucous membrane. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Key benefits of buying this profile include:


Mar 21, 2022: Orexo Notice of Annual General Meeting
Mar 11, 2022: Orexo appoints Fredrik Jarrsten as new CFO
Jan 27, 2022: Orexo Q4 2021, full Year Report
Jan 20, 2022: Invitation to presentation of the Q4 Interim Report, on January 27 at 2 pm CET
Nov 26, 2021: Orexo provides information about its new proprietary drug delivery platform - amorphO

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Orexo AB - Key Facts
  • Orexo AB - Key Employees
  • Orexo AB - Key Employee Biographies
  • Orexo AB - Major Products and Services
  • Orexo AB - History
  • Orexo AB - Company Statement
  • Orexo AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Orexo AB - Business Description
  • Business Segment: Digital Therapeutics
  • Overview
  • Performance
  • Business Segment: HQ & Pipeline
  • Overview
  • Performance
  • Business Segment: US Pharma
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Europe and United Kingdom
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Orexo AB - Corporate Strategy
  • Orexo AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Orexo AB - Strengths
  • Orexo AB - Weaknesses
  • Orexo AB - Opportunities
  • Orexo AB - Threats
  • Orexo AB - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Orexo AB, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • Mar 21, 2022: Orexo Notice of Annual General Meeting
  • Mar 11, 2022: Orexo appoints Fredrik Jarrsten as new CFO
  • Jan 27, 2022: Orexo Q4 2021, full Year Report
  • Jan 20, 2022: Invitation to presentation of the Q4 Interim Report, on January 27 at 2 pm CET
  • Nov 26, 2021: Orexo provides information about its new proprietary drug delivery platform - amorphOX
  • Nov 01, 2021: Orexo´s Nomination Committee for the Annual General Meeting 2022
  • Oct 22, 2021: Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET
  • Jul 15, 2021: Orexo Q2 2021 interim report
  • Jul 06, 2021: Invitation to presentation of Orexo´s Q2 Interim Report, on July 15 at 3 pm CET
  • Apr 29, 2021: Orexo Q1 2021 Interim Report

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
  • Orexo AB, Key Facts
  • Orexo AB, Key Employees
  • Orexo AB, Key Employee Biographies
  • Orexo AB, Major Products and Services
  • Orexo AB, History
  • Orexo AB, Subsidiaries
  • Orexo AB, Key Competitors
  • Orexo AB, Ratios based on current share price
  • Orexo AB, Annual Ratios
  • Orexo AB, Interim Ratios
  • Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Orexo AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Orexo AB, Performance Chart (2017 - 2021)
  • Orexo AB, Ratio Charts
  • Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Indivior Plc
  • Hansa Biopharma AB
  • Karo Pharma AB
  • Abliva AB
  • SpectraCure AB